News

Chief Medical Officer at Central DuPage Hospital Dr. Tom Moran joins Bob Sirott to talk about the risks of sitting for too ...
Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...
An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and Wegovy can halt and even reverse a ...
Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine.
A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...
Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...
The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...
A decision is expected in the fourth quarter of 2025.
Semaglutide - the active ingredient in medications like Ozempic and WeGovy - is only FDA approved for Type-2 diabetes, but ...
CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...